MOTS-c
MOTS-c: The Mitochondrial Peptide We Are Watching
NCT07505745 is a live Phase 2a RCT testing MOTS-c for insulin sensitivity. Here is what the trial is testing and why it matters.
MOTS-c
MOTS-c
MOTS-c and the July 23 Decision That Could End Compounding Access
MOTS-c is the only peptide with two human trials. One proved it worked — then the company dissolved. The second is running. July 23, the FDA decides compounding access.
MOTS-c
MOTS-c: The Mitochondrial Peptide Most Clinicians Don't Know About
A 16-amino-acid peptide encoded by mitochondrial DNA is generating compelling early metabolic data.